IL100942A0 - 2,4-diaminoquinazoline derivatives for enhancing antitumor activity - Google Patents
2,4-diaminoquinazoline derivatives for enhancing antitumor activityInfo
- Publication number
- IL100942A0 IL100942A0 IL100942A IL10094292A IL100942A0 IL 100942 A0 IL100942 A0 IL 100942A0 IL 100942 A IL100942 A IL 100942A IL 10094292 A IL10094292 A IL 10094292A IL 100942 A0 IL100942 A0 IL 100942A0
- Authority
- IL
- Israel
- Prior art keywords
- antitumor activity
- enhancing antitumor
- diaminoquinazoline derivatives
- diaminoquinazoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65792291A | 1991-02-20 | 1991-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL100942A0 true IL100942A0 (en) | 1992-11-15 |
Family
ID=24639196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL100942A IL100942A0 (en) | 1991-02-20 | 1992-02-13 | 2,4-diaminoquinazoline derivatives for enhancing antitumor activity |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0572437B1 (de) |
JP (1) | JPH06500117A (de) |
KR (1) | KR930703270A (de) |
CN (1) | CN1064271A (de) |
AT (1) | ATE121735T1 (de) |
AU (1) | AU655798B2 (de) |
BR (1) | BR9205645A (de) |
CA (1) | CA2101542A1 (de) |
CZ (1) | CZ387292A3 (de) |
DE (2) | DE69202243T2 (de) |
DK (1) | DK0572437T3 (de) |
ES (1) | ES2071484T3 (de) |
FI (1) | FI933656A0 (de) |
HU (1) | HUT64755A (de) |
IE (1) | IE920522A1 (de) |
IL (1) | IL100942A0 (de) |
MX (1) | MX9200675A (de) |
NO (1) | NO932954L (de) |
NZ (1) | NZ241627A (de) |
PT (1) | PT100132A (de) |
WO (1) | WO1992014716A1 (de) |
YU (1) | YU17092A (de) |
ZA (1) | ZA921911B (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
ES2049659B1 (es) * | 1992-10-08 | 1994-10-16 | Ici Plc | Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena. |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
DE4429026C2 (de) * | 1994-08-16 | 1995-11-16 | Mueller Wolfgang | Inlay-Entfernungsinstrumentarium für Totalendoprothese |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
JPH11507329A (ja) * | 1995-04-27 | 1999-06-29 | ゼネカ リミテッド | キナゾリン誘導体 |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
WO1997020822A1 (en) * | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
PT1676845E (pt) | 1999-11-05 | 2008-08-05 | Astrazeneca Ab | Novos derivados de quinazolina |
AU2001240150A1 (en) * | 2000-03-13 | 2001-09-24 | Chemrx Advanced Technologies, Inc. | Quinazoline synthesis |
CN1240688C (zh) | 2000-04-07 | 2006-02-08 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
AU2002361846A1 (en) * | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
EP1660092A2 (de) * | 2003-07-03 | 2006-05-31 | Myriad Genetics, Inc. | 4-arylamino-chinazoline als aktivatoren von caspasen und apoptose-auslöser |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
JP2007269629A (ja) * | 2004-06-21 | 2007-10-18 | Astellas Pharma Inc | キナゾリン誘導体 |
WO2006014420A1 (en) * | 2004-07-06 | 2006-02-09 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
CA2592971A1 (en) * | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Method of treating brain cancer |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
EP1833482A4 (de) * | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | Verbindungen und ihre therapeutische verwendung |
JP2009518359A (ja) * | 2005-12-07 | 2009-05-07 | ノイロサーチ アクティーゼルスカブ | 新規なキナゾリン−2,4−ジアミン誘導体及び小コンダクタンスカルシウム依存性カリウムチャネルの調節剤としてのそれらの使用 |
CN101100466B (zh) | 2006-07-05 | 2013-12-25 | 天津和美生物技术有限公司 | 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用 |
WO2008086462A2 (en) * | 2007-01-11 | 2008-07-17 | Wyeth | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS |
US20100317607A1 (en) * | 2007-06-27 | 2010-12-16 | Infectious Disease Research Institute | Use of compounds for preparing anti-tuberculosis agents |
WO2011140527A2 (en) | 2010-05-07 | 2011-11-10 | California Institute Of Technology And The University Of Kansas | Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase |
WO2018212774A1 (en) * | 2017-05-17 | 2018-11-22 | Vanderbilt University | Quinazoline compounds as modulators of ras signaling |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3663706A (en) * | 1969-09-29 | 1972-05-16 | Pfizer | Use of 2,4-diaminoquinazolines as hypotensive agents |
IL88507A (en) * | 1987-12-03 | 1993-02-21 | Smithkline Beckman Intercredit | 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them |
AU610328B2 (en) * | 1987-12-03 | 1991-05-16 | Smithkline Beckman Intercredit B.V. | 2,4- diaminoquinazoline derivatives |
-
1992
- 1992-01-08 DE DE69202243T patent/DE69202243T2/de not_active Expired - Fee Related
- 1992-01-08 EP EP92903632A patent/EP0572437B1/de not_active Expired - Lifetime
- 1992-01-08 CA CA002101542A patent/CA2101542A1/en not_active Abandoned
- 1992-01-08 WO PCT/US1992/000028 patent/WO1992014716A1/en active IP Right Grant
- 1992-01-08 HU HU9302384A patent/HUT64755A/hu unknown
- 1992-01-08 CZ CS923872A patent/CZ387292A3/cs unknown
- 1992-01-08 BR BR9205645A patent/BR9205645A/pt not_active Application Discontinuation
- 1992-01-08 DK DK92903632.5T patent/DK0572437T3/da active
- 1992-01-08 JP JP4503777A patent/JPH06500117A/ja active Pending
- 1992-01-08 ES ES92903632T patent/ES2071484T3/es not_active Expired - Lifetime
- 1992-01-08 AU AU11848/92A patent/AU655798B2/en not_active Expired - Fee Related
- 1992-01-08 AT AT92903632T patent/ATE121735T1/de not_active IP Right Cessation
- 1992-01-08 DE DE9290018U patent/DE9290018U1/de not_active Expired - Lifetime
- 1992-01-08 KR KR1019930702481A patent/KR930703270A/ko not_active Application Discontinuation
- 1992-02-13 IL IL100942A patent/IL100942A0/xx unknown
- 1992-02-17 NZ NZ241627A patent/NZ241627A/xx unknown
- 1992-02-18 PT PT100132A patent/PT100132A/pt not_active Application Discontinuation
- 1992-02-18 MX MX9200675A patent/MX9200675A/es unknown
- 1992-02-19 YU YU17092A patent/YU17092A/sh unknown
- 1992-02-19 CN CN92101113A patent/CN1064271A/zh active Pending
- 1992-02-19 ZA ZA921191A patent/ZA921911B/xx unknown
- 1992-02-19 IE IE052292A patent/IE920522A1/en not_active Application Discontinuation
-
1993
- 1993-08-19 FI FI933656A patent/FI933656A0/fi not_active Application Discontinuation
- 1993-08-19 NO NO93932954A patent/NO932954L/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP0572437A1 (de) | 1993-12-08 |
AU1184892A (en) | 1992-09-15 |
DK0572437T3 (da) | 1995-07-03 |
BR9205645A (pt) | 1994-06-07 |
NO932954D0 (no) | 1993-08-19 |
YU17092A (sh) | 1994-12-28 |
KR930703270A (ko) | 1993-11-29 |
FI933656A (fi) | 1993-08-19 |
CZ387292A3 (en) | 1994-04-13 |
IE920522A1 (en) | 1992-08-26 |
NZ241627A (en) | 1993-06-25 |
CN1064271A (zh) | 1992-09-09 |
DE69202243T2 (de) | 1995-08-31 |
ES2071484T3 (es) | 1995-06-16 |
HU9302384D0 (en) | 1993-11-29 |
NO932954L (no) | 1993-08-19 |
WO1992014716A1 (en) | 1992-09-03 |
FI933656A0 (fi) | 1993-08-19 |
HUT64755A (en) | 1994-02-28 |
AU655798B2 (en) | 1995-01-12 |
CA2101542A1 (en) | 1992-08-21 |
ATE121735T1 (de) | 1995-05-15 |
ZA921911B (en) | 1993-08-19 |
DE9290018U1 (de) | 1993-10-14 |
MX9200675A (es) | 1992-08-01 |
JPH06500117A (ja) | 1994-01-06 |
PT100132A (pt) | 1993-05-31 |
EP0572437B1 (de) | 1995-04-26 |
DE69202243D1 (de) | 1995-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL100942A0 (en) | 2,4-diaminoquinazoline derivatives for enhancing antitumor activity | |
GR3017122T3 (en) | Quinazolines derivatives for enhancing antitumor activity. | |
DE69716135D1 (en) | In 6-position durch thio substituierte paclitaxele | |
EP0659209A4 (de) | Krebstherapie unter verwendung maligner zellen. | |
GR3032723T3 (en) | 10-desacetoxytaxol derivatives. | |
IN170909B (de) | ||
GR3015921T3 (en) | Pyrimidine derivatives for enhancing antitumor activity. | |
TW282455B (de) | ||
CA1265159C (en) | GEM-DIHALOGENO-1,8-DIAMINO-4-AZA-OCTANES | |
EP0654995A1 (de) | 4-oxa-1-azabicyclo(3,2,0)heptan-7-one -derivate als antitumorwirkstoffe. | |
RU93054001A (ru) | 2,4-диаминохиназолиновые производные, способ их получения фармацевтическая композиция, способ ингибирования р-гликопротеина |